Marcus Broman1, Max Bell2,3, Olivier Joannes-Boyau4, Claudio Ronco5,6. 1. Department of Perioperative and Intensive Care, Skåne University Hospital, Lund, Sweden. 2. Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. 3. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. 4. University Hospital of Bordeaux, Bordeaux, France. 5. Department of Nephrology, St Bortolo Hospital, Vicenza, Italy. 6. International Renal Research Institute Vicenza, Vicenza, Italy.
Abstract
BACKGROUND/AIMS: We assessed how the novel PrisMax continuous renal replacement therapy (CRRT) system performed in a prospective international multicentre setting. We compared this device to its predecessor, the Prismaflex, with regards to multiple treatment parameters. Additionally, we performed a survey, aiming to measure user satisfaction. METHODS: Data was prospectively collected from 7 intensive care units (ICU) in 6 countries. The PrisMax device data logs constituted the raw material. Clinical parameters like treatment time, filter life span, downtime, delivered dose and number and type of alarms were recorded. A user questionnaire was sent out to 3 of the participating ICUs. RESULTS: Filter life, downtime, blood pump stops, bag changing time and number of malfunction alarms showed significantly improved values compared to the historic Prismaflex data. The survey showed high scores with regards to user friendliness. CONCLUSION: The PrisMax CRRT device is safe and outperformed its' previous generation counterpart in virtually all aspects. Video Journal Club "Cappuccino with Claudio Ronco" at http://www.karger.com/?doi=489213. The Author(s). Published by S. Karger AG, Basel.
BACKGROUND/AIMS: We assessed how the novel PrisMax continuous renal replacement therapy (CRRT) system performed in a prospective international multicentre setting. We compared this device to its predecessor, the Prismaflex, with regards to multiple treatment parameters. Additionally, we performed a survey, aiming to measure user satisfaction. METHODS: Data was prospectively collected from 7 intensive care units (ICU) in 6 countries. The PrisMax device data logs constituted the raw material. Clinical parameters like treatment time, filter life span, downtime, delivered dose and number and type of alarms were recorded. A user questionnaire was sent out to 3 of the participating ICUs. RESULTS: Filter life, downtime, blood pump stops, bag changing time and number of malfunction alarms showed significantly improved values compared to the historic Prismaflex data. The survey showed high scores with regards to user friendliness. CONCLUSION: The PrisMax CRRT device is safe and outperformed its' previous generation counterpart in virtually all aspects. Video Journal Club "Cappuccino with Claudio Ronco" at http://www.karger.com/?doi=489213. The Author(s). Published by S. Karger AG, Basel.
Authors: Rinaldo Bellomo; Alan Cass; Louise Cole; Simon Finfer; Martin Gallagher; Serigne Lo; Colin McArthur; Shay McGuinness; John Myburgh; Robyn Norton; Carlos Scheinkestel; Steve Su Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: Alexander Zarbock; John A Kellum; Christoph Schmidt; Hugo Van Aken; Carola Wempe; Hermann Pavenstädt; Andreea Boanta; Joachim Gerß; Melanie Meersch Journal: JAMA Date: 2016 May 24-31 Impact factor: 56.272
Authors: Paul M Palevsky; Jane Hongyuan Zhang; Theresa Z O'Connor; Glenn M Chertow; Susan T Crowley; Devasmita Choudhury; Kevin Finkel; John A Kellum; Emil Paganini; Roland M H Schein; Mark W Smith; Kathleen M Swanson; B Taylor Thompson; Anitha Vijayan; Suzanne Watnick; Robert A Star; Peter Peduzzi Journal: N Engl J Med Date: 2008-05-20 Impact factor: 91.245
Authors: Ashita J Tolwani; Mary B Prendergast; Rajesh R Speer; Brenda S Stofan; Keith M Wille Journal: Clin J Am Soc Nephrol Date: 2005-11-23 Impact factor: 8.237